CTRI/2020/08/027200尚未招募未知
AN OPEN LABEL, RANDOMIZED, TWO TREATMENT, TWO PERIOD, SINGLE DOSE & MULTIPLE DOSE, TWO-ARM, TWO WAY CROSSOVER, STEADY STATE STUDY TO ASSESS THE PHARMACOKINETIC PROFILE AND COMPARE THE DPP-4 INHIBITION ACTIVITY OF VILDAGLIPTIN MR 100MG TABLET QD [TEST PRODUCT (A)] OF NOVARTIS HEALTHCARE PVT LTD, INDIA WITH VILDAGLIPTIN 50 MG IR TABLETS BID [REFERENCE PRODUCT (B)] OF NOVARTIS HEALTHCARE PVT. LTD, INDIA IN HEALTHY ADULT, HUMAN SUBJECTS, UNDER FASTING CONDITIONS.
ovartis India Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1. Body Mass Index of 18.50 to 29.90 Kg per meter square (both inclusive).
- •2. No evidence of underlying disease during the pre-study screening, medical history, physical examination and laboratory investigations performed within 21 days prior to commencement of the study.
- •3. Pre-study screening laboratory tests within normal or clinically non-significant limits as mentioned in lab values reference range in appendix four.
- •4. Negative test results for alcohol (in breath), negative urine drugs of abuse.
- •5. Who is negative or non-reactive for antibodies to HIV 1 and 2, hepatitis B & C and RPR.
- •6. 12 lead ECG recording either normal or clinically non-significant as per Investigator opinion.
- •7. Normal or clinically acceptable chest X-ray (PA) taken within 06 months before the day of dosing.
- •8. Who will be available for the entire study period and is capable of understanding and communicating with the investigators and clinical study facility staff.
- •9. Female volunteers having a negative result in urine pregnancy test during screening and at the time of check-in.
- •10. Females with child-bearing potential must agree to use an acceptable method of contraception at least 2 days prior to dosing of IP, during the study & for 07 days following their last dose of IP. A standardized reliable method with Pearl index equal to 1 or lower should be used.
- •12. Male subjects and, or Female subjectâ??s partner must agree to use condoms, vasectomy or spermicide in addition to female contraception for additional protection against conception throughout the study and 07 days after last dose of IP.
排除标准
- •1. Known allergic to Vildagliptin or any component of the formulation and to any other related drug.
- •2. History or presence of significant cardiovascular, respiratory, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, musculoskeletal, neurological or psychiatric disease and malignancy.
- •3. Female volunteers who are breast feeding or are found positive in urine pregnancy test.
- •4. History or presence of significant alcohol dependence (abuse) or drug abuse within the past 1 year, current alcohol abuse (more than 5 units per week, 1 unit equal to 10 mL or 8 g of pure alcohol) or suspected abuse.
- •5. History of chronic smoking (more than 10 units per day of cigarettes, bidis, or any other form) or chronic consumption of tobacco products.
- •6. History/presence of Asthma, urticaria or other allergic type reactions after taking any medication.
- •7. History of vascular collapse.
- •8. Who is scheduled for surgery any time during study or within 07 days after study completion.
- •9. Who is participating in any other clinical or bioequivalence study or otherwise would have donated in excess of 350 mL of blood in the last 90 days.
- •10. Who has taken prescription medication or OTC products (including vitamins and natural products) within 14 days prior to dosing of IP in Period 1, including topical medication.
- •11. Who was hospitalized within 28 days prior to administration of the study medication.
- •12. History of difficulty in swallowing.
- •13. Who has unsuitable veins for repeated venipuncture.
- •14. Any abnormal laboratory value or physical finding which may interfere with the interpretation of test results or cause a health hazard for the volunteer if he participates in the study.
- •15. Who has Systolic blood pressure less than 90 mm of Hg or more than 140 mm of Hg.
- •16. Who has Diastolic blood pressure less than 60 mm of Hg or more than 90 mm of Hg.
研究者
相似试验
已完成
不适用
The study will be conducted to monitor safety and compare the bioavailability of Capecitabine 500 mg tablets of Sun Pharmaceutical Industries Limited, India, and Xeloda (Capecitabine) 500 mg of Roche Registration Ltd. after administration of single dose, in Cancer patients under fed conditions.CTRI/2011/10/002090Sun Pharmaceutical Industries Ltd44
尚未招募
不适用
BIOEQUIVALENCE STUDY OF NILUTAMIDE TABLET, 150 MG WITH NILANDRON (NILUTAMIDE) TABLET, 150 MG IN METASTATIC PROSTATE CANCER PATIENTS UNDER FED CONDITION.CTRI/2015/12/006440Stason Pharmaceutical Inc36
暂停
不适用
To monitor the safety and to assess bioequivalence of Bortezomib for injection, 3.5 mg/vial (1.3 mg/m2 dose) of Sun Pharmaceutical Industries Limited and Velcade (Bortezomib) for injection 3.5 mg/vial (1.3 mg/m2 dose) of Millennium Pharmaceuticals, in multiple myeloma patients, under fed conditions.CTRI/2013/12/004235Sun Pharmaceutical Industries Ltd40
Unknown
1 期
Pharmacology study of brimonidineCTRI/2016/01/006491Sun Pharma Advanced Research Company Limited24
已完成
不适用
To monitor safety and assess bioequivalence of Leuprolide Acetate 7.5 mg Depot suspension of Sun Pharmaceutical Industries Limited,India and Lupron Depot 7.5 mg depot suspension of TAP Pharmaceutical Inc., USA under fasting conditions in prostatic carcinoma patients undergoing initial therapy.CTRI/2012/02/002436Sun Pharmaceutical Industries Ltd60